Released Presentations
-
IP19 : STRUCTURAL IMPLEMENTATION OF PATIENT PREFERENCES IN HEALTH TECHNOLOGY ASSESSMENT: WILL WE EVER GET THERE? A QUESTION RAISED BY IMI PREFER
Presentation
David Mott
Economist, Office of Health Economics, London, UK
Dr. Marco Petschulies
Scientific Advisor, Federal Joint Committee (G-BA), Berlin, Germany
Eline van Overbeeke
PhD researcher, University of Leuven, Leuven, Belgium
-
IP25 : Should Nutritional Products Be Evaluated and Reimbursed The Same Way Pharmaceuticals Are?
-
P1 : Aligning Evidence Requirements for Drug Authorization and Coverage –Central and Eastern European (CEE) Countries Insights
-
P2 : Health Data, Health Data, and More Health Data: From Quantity to Quality Through Cooperation
-
P3 : Medical Device Assessment and Procurement - Fair and Efficient Access in Countries with Limited Health Budgets
-
P4 : How Far Can We Go? Finding a Common Way in Clinical Evaluation, Data Generation, and Joint Procurement and Pricing Negotiations
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?
-
PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?
-
PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?
-
PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?
-
S1 : Improving Patient Access to Innovative Cancer Therapies: The Role of Managed Entry Agreements
-
S2 : The Implementation of Sustainable Biosimilar Policies to Increase Access to Biological Medicines in CEE Countries
-
W7 : Preference Research in HTA Agencies Europe